

Annexe N

Glossary

February 2007

OFT885n

© **Crown copyright 2007**

This publication (excluding the OFT logo) may be reproduced free of charge in any format or medium provided that it is reproduced accurately and not used in a misleading context. The material must be acknowledged as crown copyright and the title of the publication specified.

GLOSSARY

| | |
|---------------|---|
| A2RA | Angiotensin-II Receptor Antagonist |
| ABPI | Association of the British Pharmaceutical Industry |
| ACE | Angiotensin Converting Enzyme |
| ACTS | Advisory Committee on Technology Selection |
| ADQ | Average Daily Quantity |
| ADTC | Area Drug and Therapeutics Committee |
| AEMPS | Agencia Espanola del Medicamento y Productos Sanitarios (Spanish Medicines Agency) |
| AFR | Annual Financial Return |
| AHB | Area Health Board |
| AMP | Average Manufacturer Price |
| ARMA | Arthritis and Musculoskeletal Alliance |
| ASMR | Improvement in the Medical Service Rendered |
| ATC | Anatomical Therapeutic Chemical |
| AUSFTA | Australia-United States Free Trade Agreement |
| AWDCC | All Wales Drug Contracting Committee |
| AWMSG | All-Wales Medicines Strategy Group |
| AWP | Average Wholesale Price |
| AWPAG | All-Wales Prescribing Advisory Group |
| BAG | Ministry of Health in Switzerland |
| BERD | Business Expenditure on Research and Development |
| BfArM | Federal Institute for Pharmaceuticals and Medical Devices (Germany) |
| BIA | BioIndustry Association |

| | |
|--------------|---|
| BMA | British Medical Association |
| BMG | Bundesministerium fuer Gesundheit (German Ministry of Health) |
| BMI | Body Mass Index |
| BMJ | British Medical Journal |
| BMS | Bristol-Myers Squibb |
| BNF | British National Formulary |
| CABG | Coronary Artery Bypass Graft |
| CADTH | Canadian Agency for Drugs and Technologies in Health |
| CCA | Current Cost Accounting |
| CE | Cost Effectiveness |
| CEPS | Comité Economique des Produits de Santé (French drug pricing agency) |
| CFI | Court of First Instance |
| CHD | Coronary Heart Disease - |
| CHTE | Centre for Health Technology Evaluation |
| C-Min | Cost Minimisation |
| CMS | Center for Medicare & Medicaid Services |
| CODEM | Committee for the Evaluation of Medicinal Products for Human Use |
| COGS | Cost of Goods Sold |
| COPD | Chronic Obstructive Pulmonary Disorder |
| CPI | Consumer Price Index |
| CRDUY | Centre for Reviews and Dissemination at the University of York |
| CUP | Comparable Uncontrolled Price |
| CURE | Clopidogrel in Unstable angina to prevent Recurrent ischemic Events |
| CVD | Cardiovascular Disease |

| | |
|-----------------|--|
| CVM | Commission on the Value of Medicines |
| CVZ | Health Insurance Board (in the Netherlands) |
| DALYs | Disability Adjusted Life Years |
| DDD | Defined Daily Dose |
| DFID | Department for International Development |
| DGFPS | Directorate General of Pharmacy and Health Products |
| DH | Department of Health |
| DHSSPSNI | Department of Health, Social Services and Public Safety of Northern Ireland |
| DQTC | Drug Quality and Therapeutics Committee |
| DTC | Direct to Consumer |
| DTI | Department of Trade and Industry |
| EC | European Community |
| ECJ | European Court of Justice |
| EEC | European Economic Community |
| EEF | Manufacturer's Association (Engineering Employers Federation) |
| EER | Equilibrium Exchange Rate |
| EFPIA | European Federation of Pharmaceutical Industries Association |
| EMA | European Medicines Agency |
| EMIG | Ethical Medicines Industry Group |
| EphMRA | European Pharmaceutical Marketing Research Association |
| EPMU | Environmental Protection Medical Unit |
| ERNIE | Evaluation and Review of NICE Implementation Evidence |
| EU | European Union |
| FA | Framework Agreement |

| | |
|---------------|--|
| FAD | Final Appraisal Determination |
| FASB | Financial Accounting Standards Board |
| FDA | Food and Drug Administration |
| FTC | Federal Trade Commission |
| FTE | Full Time Equivalent |
| FTSE | Financial Times Stock Exchange |
| GBA | Gemeinsamer Bundesausschuss (German 'Joint Committee') |
| GBAORD | Government Budget Appropriations or Outlays on Research and Development |
| GDP | Gross Domestic Product |
| GMS | General Medical Services (Ireland) |
| GORD | Gastro-oesophageal reflux disease |
| GP | General Practitioner |
| GPRD | General Practice Research Database |
| GSK | GlaxoSmithKline |
| GVS | Maximum Reimbursement Price (Netherlands) |
| GW | Glaxo Wellcome |
| HAS | Haute Autorité de Santé (French National Health Authority) |
| HCA | Healthcare Communications Association |
| HDAP | Human Drug Advisory Panel |
| HDL | High Density Lipoprotein |
| HEC | Health Evaluation Centre |
| HIW | Healthcare Inspectorate Wales |
| HMO | Health Maintenance Organisations (US) |
| HMRC | Her Majesty's Revenue and Customs |
| HMT | Her Majesty's Treasury |

| | |
|--------------|--|
| HPS | Health Protection Scotland |
| HSE | Irish Health Service Executive |
| HSW | Health Solutions Wales |
| HTA | Health Technology Assessment |
| IASB | International Accounting Standards Board |
| ICER | Incremental Cost Effectiveness Ratio |
| IFS | Institute of Fiscal Studies |
| IHS | Indian Health Service (US) |
| IND | Investigational New Drug |
| IP | Intellectual Property |
| IPPR | Institute for Public Policy Research |
| IQWiG | Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, (Germany, independent federal institute for the evaluation of medical efficiency, quality and effectiveness) |
| IRP | International Reference Pricing |
| IRR | Internal Rate of Return |
| ISD | Information Services Division |
| Kela | Finnish Social Insurance Institution |
| LBS | London Business School |
| LDL | Low Density Lipoprotein |
| LDLC | Low Density Lipoprotein Cholesterol |
| LFN | Pharmaceutical benefits board (Sweden) |
| LHB | Local Health Board |
| LNDG | London New Drugs Group |
| LSE | London School of Economics |
| MAC | Maximum Allowable Cost |

| | |
|---------------|---|
| MCO | Managed Care Organization (US) |
| MHRA | Medicines and Healthcare products Regulatory Agency |
| MIMS | Monthly Index of Medical Specialities |
| MISG | Ministerial Industry Strategy Group |
| MMSE | Mini Mental State Examination |
| MOT | Margin of Tolerance |
| MPC | Medicines Pricing Commission |
| MR | Modified Release |
| MRC | Medical Research Council |
| MS | Multiple Sclerosis |
| MSD | Merck Sharp & Dohme Limited (UK subsidiary of Merck & Co.) |
| MTA | Multiple Technology Appraisal |
| NAO | National Audit Office |
| NAS | New Active Substance |
| NBER | National Bureaux of Economic Research |
| NCCHTA | National Coordinating Centre for Health Technology Assessment |
| NCE | New Chemical Entity |
| NDC | New Drugs Committee |
| NELM | National Electronic Library for Medicines |
| NERA | National Economic Research Associates (Economic consultancy firm) |
| NFA | National Framework Agreement |
| NHS | National Health Service |
| NIC | Net Ingredient Cost |
| NICE | National Institute for Health and Clinical Excellence |
| NIHR | National Institute for Health Research |

| | |
|--------------|--|
| NME | New Molecular Entity |
| NPC | National Prescribing Centre |
| NPfIT | NHS National Programme for IT |
| NPO | National Procurement Organisation |
| NPS | National Pharmaceutical Society |
| NPS | National Pharmaceutical Strategy (Canada) |
| NPV | Net Present Value |
| NSAID | Non-Steroidal Anti-Inflammatory Drug |
| NSCAG | National Specialist Commissioning Advisory Group |
| NSF | National Service Framework |
| NZa | Healthcare Authority (Netherlands) |
| OECD | Organisation for Economic Co-operation and Development |
| Ofgem | Office of Gas and Electricity Markets |
| OFT | Office of Fair Trading |
| Ofwat | Water Services Regulation Authority |
| OHE | Office of Health Economics |
| OOP | Out-of-Pocket Costs |
| OSCHR | Office for Strategic Coordination of Health Research |
| OST | Office of Science and Technology |
| OTC | Over the Counter (drugs) |
| OXERA | Oxford Economic Research Associates (Economic consultancy firm) |
| PA | Prescribing Adviser |
| PACT | Prescribing Analysis and Cost Tabulations |
| PAPI | Patient and Public Involvement Group |

| | |
|--------------|---|
| PASA | Purchasing and Supplies Agency |
| PBAC | Pharmaceutical Benefits Advisory Committee (Australia) |
| PBC | Practice Based Commissioning |
| PBM | Pharmaceutical Benefit Manager (US) |
| PBPA | Pharmaceutical Benefits Pricing Authority (Australia) |
| PBR | Payment by Results |
| PBS | Pharmaceutical Benefits Scheme (Australia) |
| PCA | Prescription Cost Analysis |
| PCMA | Pharmaceutical Care Management Association |
| PCO | Primary Care Organisation |
| PCT | Primary Care Trust |
| PhRMA | Pharmaceutical Research and Manufacturers of America |
| PICTF | Pharmaceutical Industry Competitiveness Task Force |
| PMPRB | Patented Medicines Price Review Board (Canada) |
| PMS | Personal Medical Services |
| POS | Point of Service Plan (US) |
| PPA | Prescription Pricing Authority |
| PPB | Pharmaceuticals Pricing Board |
| PPD | Prescription Pricing Division |
| PPI | Proton Pump Inhibitor |
| PPO | Preferred Provider Organisation (US) |
| PPP | Purchasing Power Parity |
| PPRS | Pharmaceutical Price Regulation Scheme |
| PSG | Pharmacy Service Group |

| | |
|----------------|---|
| PSNC | Pharmaceutical Services Negotiating Committee |
| PSS | Personal Social Services |
| PTCA | Percutaneous Transluminal Coronary Angioplasty |
| PVA | Price Volume Agreements |
| P&T | Pharmacy and Therapeutic |
| QALYs | Quality Adjusted Life Years |
| QOF | Quality and Outcomes Framework |
| RCTs | Randomised Controlled Trials |
| R&D | Research and Development |
| ROC | Return on Capital |
| ROCE | Return on Capital Employed |
| ROHTO | National Centre for Pharmacotherapy Development (Finland) |
| ROS | Return on Sales |
| RPBS | Repatriation pharmaceutical benefit scheme |
| RPI | Retail Prices Index |
| RSS | Regional Supplies Service (Northern Ireland) |
| SBU | Swedish Council on Technology Assessment in Health Care |
| ScHARR | School of Health and Related Research at the University of Sheffield |
| SCHIP | State Children's Health Insurance Program |
| SD | Standard Deviation |
| SEHD | Scottish Executive Health Department |
| SHF | Statutory Health Fund |
| SHI | Social Health Insurer's Organisation |
| SHTAC | Southampton Health Technology Assessment Centre |
| SIGN | Scottish Intercollegiate Guidelines Network |

| | |
|---------------------------|--|
| SMC | Scottish Medicines Consortium |
| SME | Small or Medium Sized Company |
| SMR | Medical Service Rendered (France) |
| SPC | Supplementary Protection Certificate |
| SPG | Scottish Pharmacologists Group |
| SSRI | Selective Serotonin Re-uptake Inhibitor |
| STA | Single Technology Appraisal |
| STEPS | Safe Therapeutic Economic Pharmaceutical Selection |
| TC | Total Cholesterol |
| TGA | Therapeutic Goods Administration |
| TMFB | Translational Medicines Funding Board |
| Anti-TNF Therapies | Anti-tumour Necrosis Factor Therapies |
| UCL | University College London |
| UCLA | University of California, Los Angeles |
| UCLH | University College London Hospitals |
| UKCRC | UK Clinical Research Collaboration |
| UKCRN | UK Clinical Research Network |
| UKTI | UK Trade and Investment |
| VA | Veterans Association (US) |
| VAT | Value Added Tax |
| VC | Venture Capital |
| VPRS | Voluntary Price Regulation Scheme |
| WAGHD | Welsh Assembly Government Health Department |
| WAMTC | Weighted Average Monthly Treatment Cost (Australia) |

| | |
|----------------|--|
| WHO | World Health Organisation |
| WIHRDUS | Wessex Institute for Health Research and Development at the University of Southampton |
| WMP | Welsh Medicines Partnership |
| WTO | World Trade Organisation |
| WTP | Willingness to Pay |